Microgravity Drug Activity Determination Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective way to determine the activity of drugs or drug candidates and predict their suitability for treating or preventing diseases, as well as influencing the aging process, under conditions that mimic real-world disease scenarios.
Innovation Solution
A method involving monocytic cell lines or stimulated peripheral blood mononuclear cells (PBMCs) is used, where cells are subjected to microgravity conditions and exposed to drugs or drug candidates. RNA and protein expression are then compared to determine the drug's suitability for treating diseases or influencing aging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional in-vitro model systems are used to study diseases and cellular responses, then basic physiological and pathological processes can be studied, but the ability to accurately predict drug activity under real-world disease conditions and aging scenarios is insufficient
Solution Approach 1:
The patent applies parameter changes by subjecting cells to microgravity conditions, which fundamentally alters the physiological state of the cells. This parameter change (from standard gravity to microgravity) creates a more accurate disease model that better reflects in-vivo conditions, thereby improving both measurement precision of drug activity and adaptability to simulate real disease scenarios simultaneously
2Measurement precision
If microgravity conditions are applied to cells to simulate disease conditions, then drug activity determination accuracy improves, but experimental complexity and resource requirements increase
Solution Approach 1:
The patent uses cell cultures as simplified copies or models of complex in-vivo systems. By creating in-vitro cell models that respond to microgravity similarly to how actual tissues would respond in the human body, the patent achieves accurate drug prediction without requiring complex in-vivo experimentation, thus improving measurement precision while managing device complexity
Data Source
AI summary
The present invention relates to a method for determining the activity of a drug or drug candidate and/or for predicting suitability of a drug or drug candidate for treatment or prevention of a disease and/or for predicting suitability of a drug or drug candidate for influencing ageing.